Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial

AIM: To assess cardiovascular, glycaemic, weight and safety outcomes of long‐term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher. MATERIALS AND METHODS: Intention‐to‐treat analyses were performed on REWIND participants wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Franek, Edward, Gerstein, Hertzel C., Riddle, Matthew C., Nicolay, Claudia, Hickey, Ana, Botros, Fady T., Loo, Li Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543284/
https://www.ncbi.nlm.nih.gov/pubmed/35546279
http://dx.doi.org/10.1111/dom.14760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543284/
https://www.ncbi.nlm.nih.gov/pubmed/35546279
http://dx.doi.org/10.1111/dom.14760

Ejemplares similares